Standardized operational procedures (SOPs) for inspection, distribution, and processing of epileptogenic brain tissue will reduce sampling errors in any pathology laboratory, ensure the best possible histologic assessment, and support research activities and brain-banking initiatives. Good communication and interaction between neuropathologists, epileptologists, and neurosurgeons are considered best medical practice and could start at multidisciplinary patient management conferences, preceding epilepsy surgery. Such communication would ensure the neuropathologist's knowledge of the clinical and radiologic diagnosis, and type and aims of resection prior to receipt of the surgical specimen, thereby optimizing the yield of histopathologic assessment. To support interdisciplinary communication and strategies for reliable tissue analysis in routine clinical applications and research, the International League Against Epilepsy's (ILAE's) Neuropathology Task Force developed a simple protocol for tissue handling that can be applied worldwide.
The SOP is based on systematic sampling of 5-mm interval slabs along an anatomically defined plane of section. For optimal neuropathologic precision, anatomically intact resections (also referred to as "en bloc") are preferable. However, surgical procedures in the dominant hemisphere or close to eloquent areas will often be directed by safety considerations, and large "en bloc" samples may not be feasible. In such cases, biopsies from electrophysiologically well-characterized epileptogenic areas or lesions detected by magnetic resonance imaging (MRI) are helpful as an alternative strategy to allow histopathologic validation of the epileptogenic substrate. In complex cases, the presence of a neuropathologist in the operating room is recommended to document anatomic landmarks of the surgical specimen. The neuropathology report should specify a final diagnosis and subtype of the epileptogenic lesion and any additional pathologies noted (Table 1) , their localization, and extent in the samples submitted as well as in relation to clinical information provided, for example, epileptic lesion versus irritative versus ictal-onset zones. [1] [2] [3] Although routine light microscopic assessment stains remain the benchmark, a set of well-characterized antibody immunoreactivities has been developed to identify aberrant patterns of disease-specific protein epitopes. Recent epilepsy classification schemes for subtype-specific clinicopathologic diagnosis are built on a selected and moderate number of such antibody immunoreactivities, 4, 5 and supported by evidence from peer-reviewed research studies. [6] [7] [8] [9] [10] The Task Force recommends systematic application of these antibodies (or alternative probes when published with ample evi-
Key Points
• Neuropathology in epilepsy surgery: Standardized neuropathologic examination of brain tissue obtained from epilepsy surgery allows classification of the clinicopathologic substrate of the patient's seizure disorder. It will also help predict a patient's risk for favorable or unfavorable postsurgical seizure control. Prominent examples of such efforts are ILAE's First Consensus Classification Systems for Focal Cortical Dysplasia and Hippocampal Sclerosis. It will also improve our understanding of the underlying etiology by using well-characterized human brain tissue for advanced brain research strategies
• Recommendations for consensus protocols in the neuropathology workup: According to the recent ILAE clinicopathologic classification systems, neuropathologic assessment of epilepsy surgery specimens and neuropathology reports should apply standardized consensus terminology following protocols. This is considered paramount to the implementation of evidencebased medicine, for example, by randomized controlled clinical trials, which remain incomplete in the field of epilepsy surgery. A purpose of our presented Task Force report is to attempt to standardize the neuropathologic workup of tissue procurement, handling, and processing, with the goal of establishing an essential infrastructure for systematic neuropathologic examinations in this specialized brain surgery
• Neuropathology Task Force of the ILAE Commission on Diagnostic Methods: The ILAE Commission on Diagnostic Methods covers all major diagnostic modalities to clinically characterize and diagnose a patient's epilepsy, namely electro-/neurophysiologic, neuropsychology, imaging, and neuropathology measures. Our objective is to provide standardized protocols, terminology use, and guidelines for a costeffective diagnosis of epilepsy and their related comorbidities as well as use of consensus classification systems for underlying etiologies. The Neuropathology Task Force has been instrumental in recent clinicopathologic classification systems tested and disseminated by a collaborative virtual microscopy platform as well as a collaborative Summer School initiative, annually convening at different venues around the world, for example, 2013-2014 in Erlangen, Germany, and 2015 in Campinas, Brazil dence) as minimum standard in neuropathology laboratories in clinical centers engaged in epilepsy surgery ( Table 2 ), acknowledging that some national medical boards or public health services may not accept a given antibody or compensate for its diagnostic use.
Long-term tissue storage and archiving will become more important in modern diagnosis as new molecular tests are increasingly available, for example, IDH1 mutation and 1p/ 19q codeletion analysis in the differential diagnosis of diffuse gliomas. Clinicians may increasingly start requesting retrospective investigations or additional review of stored tissue samples for patients who underwent epilepsy surgery in the past. 11 Advanced frozen storage facilities, adequate record keeping, and protocols for microscopic review of snap frozen samples will facilitate this process and improve diagnostic accuracy if lesional tissue is available for molecular testing or for evaluation in any advanced research study.
Methods
The recommendations build upon previous work of the ILAE Neuropathology Task Force of the Diagnostic Methods commission in [2009] [2010] [2011] [2012] [2013] , that also developed clinicopathologic consensus classification systems for hippocampal sclerosis 4 and focal cortical dysplasia. 5 A detailed survey of neuropathologic protocols and brain-banking initiatives was conducted among Task Force members and from published literature to identify common practices in the field. [12] [13] [14] [15] Because most protocols are adapted to local conditions, practices, and legal regulations governing human brain tissue, this information was also helpful in defining minimum standard requirements that can be applied worldwide. With this background in mind, the Task Force for Neuropathology of the ILAE Commission on Diagnostic Methods (term 2013-2017) was charged with the task of developing a consensus recommendation for tissue inspection, distribution, and histopathologic examination. Input from our clinical and research colleagues helped define their expectations from an efficient and reliable neuropathology service working in close collaboration with the Data retrieved from the German Neuropathology Reference Center for Epilepsy Surgery. Age at onset/surgery = mean age of patients at onset of spontaneous seizure activity (in years) and surgery (in years), respectively. Dual pathology includes hippocampal sclerosis with another principal pathology. 5 Double pathology refers to two etiologically independent pathologies (hippocampal sclerosis not included). HE, hematoxylin-eosin; CV-LFB, cresyl violet-Luxol fast blue (LFB can be also combined with HE); GFAP, glial fibrillary acidic protein; MAP2, microtubule-associated protein 2 (clone HM2); NeuN, neuronal nuclei (clone A60); NFL, nonphosphorylated neurofilament protein (clone SMI32); VIM, vimentin; CD34, oncofetal class II epitope CD34 (clone QBenD10); Ki67, proliferation marker (clone Mib1); IDH1, R132H point-mutation specific antibody; CD68, antibody specific for macrophages and microglia, other epitopes shown to specifically recognize microglia can also be applied; CD3, antibody specific for T lymphocytes; HS, hippocampal sclerosis; MCD, malformation of cortical development; Vasc., vascular malformations including cavernomas and arteriovenous malformations; Infl., inflammation; Scars, resulting from brain trauma or vascular infarcts, information may be available from clinical history; no lesion, refers to histopathologic specimens in which none of the aforementioned principal histopathologic categories can be identified. This will usually require a more generous application of immunohistochemical investigations (see diagnostic values specified below).
x = recommended stains and immunoreactivities, as specified below (1-16). 1 = describe reactive gliosis in areas of neuronal loss and at surface boundaries (Chaslin's gliosis); 2 = subfield analysis of neuronal cell loss (ILAE classification of HS); 3 = to exclude cytotoxic (CD8+) T-cell infiltration in limbic encephalitis; 4 = heterotopic neurons in white matter; 5 = architectural abnormalities of cortical layering in FCD I, II, and III, and polymicrogyria; 6 = dysmorphic neurons in FCD ILAE type II, but present also in aged pyramidal cells of cortical layers III and V; 7 = balloon cells in FCD type II, but also expressed in reactive astrocytes; 8 = can be present in balloon cells in FCD type IIb; 9 = differentiates astrocytic from clear-cell oligodendrocytic-like differentiation; 10 = majority of glial cells in diffuse glioma; only neuronal expression in glioneuronal tumors; 11 = to exclude associated FCD type III a-d (ILAE classification 2011); 12 = majority of ganglioglioma and diffuse glioneuronal tumors, typically not expressed in low grade gliomas; 13 = low proliferation index (<5%) in glioneuronal tumors; 14 = reacts specifically with the R132H point mutation not present in glioneuronal tumors; 15 = to verify cytotoxic (CD8+) T-cell infiltration in limbic or Rasmussen encephalitis; 16 = use entire panel, as nonlesional epilepsy should be diagnosed only following exclusion of any other lesion pattern.
a Proposed stains and antibodies for immunohistochemical reactions have been selected from published ILAE consensus classification systems, 4, 5 and ILAE agreement studies, 17 but can be adopted by specific laboratory expertise if required (see specifications below). This list does not cover the entire spectrum of antibodies available for the differential diagnosis of brain pathology or compete with recommendations of the WHO classification system for brain tumors.
different team members while minimizing disruptions to routine workflows. The results allowed us to develop a core protocol for handling human brain tissue obtained at epilepsy surgery. We also took into account experience gained from research efforts collecting and storing human brain tissue (e.g., European Epilepsy Brain Bank; German Neuropathology Reference Center for Epilepsy Surgery), panel discussions among international epilepsy neuropathologists during international epilepsy meetings (ILAE, European Congress of Epileptology, and American Epilepsy Society meeting), and participants of the International Summer School for Neuropathology of Epilepsy Surgery. 16 Because these recommendations are aimed primarily at clinical diagnosis in patient care, the important role of human tissue research using histopathologically well-characterized tissue samples will not be systematically reviewed and discussed, nor will protocols for research be provided here.
It is the consensus of this Task Force, that state-of-theart neuropathologic workup of human brain tissue obtained during epilepsy surgery requires a minimum set of established and well-recognized stains and antibody immunoreactivities that can be utilized internationally by neuropathologists or general anatomic pathologists in most hospitals. Antibodies recommended in this work have been selected based on the following criteria. 
An Interdisciplinary Diagnostic Approach Is Required for Successful Epilepsy Surgery
Optimum histopathologic services can be achieved in a setting of collaborative interaction with epileptologists, neurosurgeons, and neuropathologists. Other disciplines involved in clinical workup including neuro-/radiologists, neurophysiologists, and neuropsychologists also contribute to increasing the expected yield from neuropathology services. This paper, therefore, will briefly review some concepts that distinguish epilepsy surgery from the neurosurgical treatment of other neurologic disorders, such as tumors and vascular malformations.
Patients undergoing epilepsy surgery generally have long-standing drug-resistant seizures. [19] [20] [21] [22] [23] A broad spectrum of histopathologic lesion categories can be encountered in this cohort, including tumors, degeneration (e.g., hippocampal sclerosis [HS]), brain malformations (e.g., FCD or cortical tubers in patients with tuberous sclerosis complex [TSC]), glial scars (traumatic brain injury, bleeding, perinatal infarcts, or any other ischemic insult), inflammation (e.g., Rasmussen's or limbic encephalitis), or vascular malformations (e.g., cavernomas, angiomatosis, arteriovenous malformations). However, in 6.5% of all patients, no specific microscopic abnormality is identified (Table 1) .
Improved high-field structural and functional neuroimaging techniques allow presurgical detection of many potentially epileptogenic focal brain lesions. 24, 25 The decision for surgical intervention, either as a curative-tailored complete resection, partial resection, or as palliative treatment (callosotomy, hemispherotomy, vagus nerve and deep brain stimulation), should then be discussed at interdisciplinary case management conferences. Counseling a patient about best available treatment options and optimum long-term risk-benefit tradeoffs requires careful considerations of all available information. 26 Ideally, the neuropathologists should be involved early, already at this point, to discuss expected results from histopathologic analyses of resected brain specimens and the likelihood of making a specific diagnosis if anatomically intact "en bloc" resections will not be made available. The extent of neurosurgical resection may largely depend on the location of a given lesion, as well as its relation to the epileptogenic, irritative, and ictal-onset zone, for example, whether it is localized in the dominant hemisphere or adjacent to eloquent cortical areas. Invasive electroencephalography (EEG) recordings are frequently carried out as part of the presurgical workup, which will also influence the histopathologic examination (see below).
Concepts in epilepsy surgery differ from those in most other neurosurgical procedures in neurooncology, brain trauma, or palliative medicine, in which nonlesional brain tissue is only rarely resected. In contrast, the main goal in epilepsy surgery is to cure epilepsy and maintain long-term seizure control, rather than to only remove a suspected brain lesion. Consequences from this strategy are multilayered and also affect the histopathologic workup. The electrophysiologically defined epileptogenic area can be larger than or even separate from an MRIevident brain lesion, and the surgical resection field could be, therefore, larger than anticipated for a lesionectomy. Consequently, histopathologic assessment may not reveal altered cortical brain structure in all surgical specimens, when samples were selected by a standardized operational procedure for inspection, distribution, and processing (see recommendations of this Task Force below). This does not imply that histologically "normal" tissue is functionally normal, as many molecular alterations that increase tissue susceptibility to seizures or decrease seizure threshold escape detection at the resolution level of light microscopy. With more advanced and refined analysis protocols, such alterations can often be identified, for example, acquired channelopathies and altered glial networks. 27, 28 However, these abnormalities may not be revealed by a routine histopathologic workup and thus will not be discussed further here. Another challenge represents the large spectrum of secondary changes resulting from intracerebral diagnostic procedures. Implantation of intracranial electrodes, either with subdural grids, strips, or depth electrodes are used increasingly and always cause reactive cellular responses, for example, presence of subpial bleeding, traces of reactive cellular (inflammatory) infiltration, and microinfarcts along the trajectory of a depth electrode. It is beyond the scope of this Task Force report to discuss all possible scenarios. However, information about such procedures should be made available to the neuropathologist together with a short summary of the patient's epilepsy history in order to differentiate bona fide epileptogenic glial scarring or inflammatory infiltrates from iatrogenic secondary changes.
In summary, an interdisciplinary approach assists the epileptologist and the neurosurgeon in fashioning an ideal resection, helps the neuropathologist to understand the clinical question, and ultimately the patient by optimizing care. A standardized histopathology report is helpful for further management of each patient's epilepsy and will improve our understanding of the underlying etiology by using wellcharacterized human brain tissue for advanced brain research strategies.
A Comprehensive Histopathology Report in Epilepsy Surgery
All histopathology reports should refer to anatomic landmarks and orientation, and clearly state a histopathologic diagnosis according to current classification systems. Relevant auxiliary clinical and diagnostic information including MRI findings should be included in the "clinical history" section of the histopathology report. In many epilepsy specimens it may be possible to determine whether resection borders are lesion-free. This is particularly applicable to focal cortical dysplasias and glioneuronal tumors. Tissue from ultrasonic aspiration may be submitted to the pathology lab and provide additional information but limit the possibility of identification of anatomic landmarks (e.g., aspirates from the amygdala) as well as any assessment of completeness of resection. Postoperative imaging also provides further information on the extent of resection.
The neuropathology laboratory should be responsible for the standardized neuropathologic tissue procurement as proposed below, which can also allow for sufficient tissue harvest for related research projects. This will ensure that tissue for molecular or any other further analysis does contain expected cellular components (lesional, perilesional, or histopathologically unaffected normal region as control). Further histopathologic assessment should systematically apply recommended stains and immunoreactivities specified in Table 2 to achieve a specific diagnosis according to international consensus 4, 5 or WHO classification systems. 29 The latter will require, however, more extensive immunohistochemical and molecular testing as different treatment strategies become increasingly available for moleculargenetic tumor subtypes.
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The standardized operational procedure for tissue inspection, distribution, and processing illustrated below anticipates most common clinical scenarios in epilepsy surgery: (1) selective amygdalohippocampectomy or combined with anterior temporal lobe resections; (2) lesionectomy or corticectomy, with or without invasive brain recordings; (3) large resections including hemispherectomy/hemispherotomy; (4) resections close to eloquent areas (which may yield, by clinical necessity, incomplete or fragmented anatomic samples); and (5) cortical resections of an MRI-negative electrophysiologically active seizure focus. The proposed protocol is, however, sufficiently flexible to adjust for local requirements, but it should encourage examination of routine practices and adoption of these recommendations where possible. This will allow for better comparison and reliable diagnostic workup of epilepsy surgery specimens.
Technical Annex
The Task Force has developed a standardized operational procedure (SOP) for tissue handling and procurement in the setting of epilepsy surgery that can be applied in any laboratory worldwide, and can adapt to local institutional requirements to minimize disruptions to routine workflows. It refers to a standardized cutting scheme using anatomic landmarks, which can be supplied by the neurosurgeon, for example, by drawings, photographs, colored ink, stitches, or staples (Figs. 1-5 ). Key practice is systematic cutting of the specimen into 5-mm interval parallel slabs along a given anatomical axis, for example, anterior-posterior or dorsalventral, and sampling for routine histopathology of every second slice. This scheme can be used for most frequent clinicopathologic scenarios in epilepsy surgery, as exemplified in Figures 1-4 , for example, selective hippocampectomy (Fig. 1) , anterior temporal lobectomy (Fig. 2) , lesionectomy with or without intracranial recordings (Figs. 3 and 4) , or cortical resection of an MRI-negative epileptogenic brain region (Fig. 5 ). This present protocol will remain open to future modifications as additional data become available. Figs. 2 and 3 ). Label all slices and document their order by photography, using an alphabetical or numerical system. Depending on the size of the specimen, alternate slices will be saved for histopathology and embedded into paraffin to allow thin cutting at 4-7 lm for routine histology, histochemical stains, as well as antibody immunoreactivities. If possible, the slice containing a macroscopic abnormality or capturing the center of the epileptogenic zone as defined by imaging and/or electrophysiology should be labeled as such. The remaining tissue blocks will become available for tissue banking and/or other research projects. 5 Slabs from the resection border should be labeled and embedded separately into paraffin for systematic histopathologic examination.
Tissue processing and storage protocols A standardized paraffin embedding protocol is recommended using commercially available semi-or fully automated equipment.
Paraffin-embedded tissue specimens should be cut with a rotatory microtome at 4-7 lm thickness (preferably at 4 lm). Blocs should be cooled to À15°C before cutting. Sections should be stretched in heated water bath at 40°C before mounting on coated glass slides. Allow drying for 30 min at 60°C or overnight at 36°C.
For tissue biobanking, unfixed tissue should be snap-frozen in isopentane (2-methylbutane), cooled to the temperature of liquid nitrogen, and stored at À80°C in appropriate tissue container (Fig. 6) . Tissue should be covered in compound cryostat embedding medium to prevent drying artifacts during long-term storage.
Standard immunohistochemistry protocol for paraffinembedded sections (can be modified according to local requirements) 1 De-paraffinize (de-wax) sections in xylene 2 9 10 min; hydrate with 100% isopropanol 5 min; hydrate with 96% isopropanol 5 min; hydrate with 70% isopropanol 5 min; rinse in distilled water. 2 Antigen retrieval to unmask antigenic determinants: boil slides for 2 9 10 min in citrate buffer (e.g., microwave). Refill buffer after first round; cool for at least 10 min and rinse 2-3 times in Tris-buffered solution (TBS). Table 2 ): Rinse 2-3 times in Tris-buffered solution (TBS); apply biotinylated secondary antibodies and incubate for 10 min; rinse 2-3 times in TBS; apply streptavidin peroxidase and incubate for 10 min; rinse 2-3 times in TBS. Apply chromogen (i.e., diaminobenzidine tetrahydrochloride) mixture to tissue section for 5-10 min (visual control of immunoreactivity); rinse in distilled water; counterstain in hematoxylin (2-5 s); rinse in water; dehydrate samples (70% isopropanol, 96% isopropanol, 100% isopropanol, xylene, 10 dips per rinse); mount coverslip using appropriate medium. 
